Search Within

Mila Gorsky

Formats
  1. Meeting Abstract (6)
  2. Journal Article (2)
Groups
  1. Breast Medicine Service (8)
  2. Department of Medicine (8)
  3. GDMT, Medicine (8)
  4. Gynecology Disease Management Team (8)
  5. Solid Tumor Oncology Division (8)
  6. Survivorship Research (7)

More Groups

People
  1. Shanu Modi (5)
  2. Tiffany Traina (5)
  3. Tiffany Troso-Sandoval (5)
  4. Artavazd Arumov (4)
  5. Ayca Gucalp (4)
  6. Diana Lake (4)

More People

Years
  1. 2022 (2)
  2. 2019 (1)
  3. 2018 (2)
  4. 2011 (1)
  5. 2009 (1)
  6. 2008 (1)
Publications
  1. Cancer Research (2)
  2. Journal of Clinical Oncology (2)
  3. Annals of Oncology (1)
  4. Breast Cancer Research and Treatment (1)
  5. Clinical Cancer Research (1)
  6. Journal of Allergy and Clinical Immunology (1)
Publishers
  1. American Association for Cancer Research (3)
  2. American Society of Clinical Oncology (2)
  3. Mosby Elsevier (1)
  4. Oxford University Press (1)
  5. Springer (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
    Meeting Abstract

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: A feasibility study
    Journal Article

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Breast Cancer Research and Treatment (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR plus ) TNBC
    Meeting Abstract

    Traina, T. A.; Boyle, L. A.; Arumov, A.; Patil, S.; Edelweiss, M.; DeFusco, P. A.; Gorsky, M.; Lamparella, N. E.; Modi, S.; Sanford, R. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Lyons, T.; Gucalp, A.; Arumov, A.; Patil, S.; Edelweiss, M.; Gorsky, M.; Troso-Sandoval, T. A.; Bromberg, J.; Sanford, R. A.; Iyengar, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clinical utility of prospective molecular characterization in advanced endometrial cancer
    Journal Article

    Soumerai, T. E.; Donoghue, M. T. A.; Bandlamudi, C.; Srinivasan, P.; Chang, M. T.; Zamarin, D.; Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Tew, W. P.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Rapid desensitization did not prevent febrile ''idiosyncratic'' reactions to oxaliplatin
    Meeting Abstract

    Mathew, A.; Ballas, M. S.; Gorsky, M.; Feigenbaum, B. A.
    Journal of Allergy and Clinical Immunology (2011)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BC): First safety results
    Meeting Abstract

    Dang, C.; Lin, N.; Lake, D.; Theodoulou, M.; Drullinsky, P.; Gorsky, M.; Chen, C.; Norton, L.; Winer, E.; Hudis, C.
    Annals of Oncology (2008)

    Fulltext@MSK | Save